Quidel Corporation

318 articles about Quidel Corporation

• Quidel Supports New NIH, CDC Public Health Initiative for At-home COVID-19 Testing

  4/1/2021

  Company is providing two million QuickVue® At-Home OTC COVID-19 Tests for “Say Yes! COVID Test” community health initiative in Pitt County, NC, and Chattanooga/Hamilton County, TN

• Quidel Partners With San Diego Padres Organization for COVID-19 Testing

  4/1/2021

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that after several months supporting the Padres Front Office’s efforts to reopen safely, Quidel has been chosen as “Official Diagnostics Partner” of the San Diego Padres Major League Baseball (MLB) franchise

• Quidel’s QuickVue® At-Home OTC COVID-19 Test Receives Emergency Use Authorization for Screening Use With Serial Testing

  4/1/2021

  Quidel Corporation announced that it has received an Emergency Use Authorization from the U.S. FDA, allowing the company to market its new QuickVue® At-Home OTC COVID-19 Test for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 from individuals with or without symptoms or other epidemiological reasons to suspect COVID-19 when tested twice over two with at least 24 hours between tests.

• Quidel’s Sofia® SARS Antigen Test Receives Emergency Use Authorization for Screening Use With Serial Testing

  4/1/2021

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), allowing the company to market its Sofia® SARS Antigen FIA

• Quidel Corporation Applauds Biden Administration Plan to Expand COVID-19 Testing

  3/18/2021

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced its support for the Biden Administration’s plan to expand COVID-19 testing in schools, underserved communities, rural areas and other settings that have been gravely impacted by the pandemic.

• Quidel Receives Emergency Use Authorization for QuickVue® At-Home COVID-19 Test

  3/1/2021

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), allowing the company to market its new QuickVue® At-Home COVID-19 Test

• Quidel to Present at Upcoming Conferences - Feb 22, 2021

  2/22/2021

  Quidel Corporation, a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it will present at the following upcoming conferences

• Quidel Reports Fourth Quarter and Full Year 2020 Financial Results

  2/18/2021

  Quidel Corporation (NASDAQ: QDEL) , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the fourth quarter and year ended December 31, 2020.

• Quidel Opens New Manufacturing Facility to Mass Produce QuickVue® Rapid Antigen Tests for COVID-19

  2/3/2021

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, today announced the opening of a new manufacturing facility in Carlsbad, CA that will be dedicated to the production of Quidel’s popular QuickVue® line of products.

• Quidel to Hold Fiscal Fourth Quarter and Full Year 2020 Financial Results Conference Call on February 18th, 2021

  1/28/2021

  Quidel to Hold Fiscal Fourth Quarter and Full Year 2020 Financial Results Conference Call on February 18 th , 2021 SAN DIEGO--( BUSINESS WIRE )-- Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year 2020 financial results after market close on Thursday, February 18, 2021. Following the release of resu

• Quidel Receives Emergency Use Authorization for Moderately Complex Solana® SARS Molecular Test for COVID-19 Diagnosis

  12/23/2020

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Solana® SARS-CoV-2 Assay, an isothermal Reverse Transcriptase - Helicase-Dependent Amplification

• Quidel Receives Emergency Use Authorization for QuickVue® SARS Rapid Antigen Test for COVID-19 Diagnosis

  12/21/2020

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its QuickVue® SARS Antigen test,

• Quidel Corporation CEO Douglas Bryant Named Executive of the Year in MedTech Dive Awards For 2020

  12/10/2020

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”) , a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel’s President and CEO Douglas Bryant was named Executive of the Year in the MedTech Dive Awards for 2020. MedTech Dive, a business publication that provides in-depth re

• Quidel Corporation Hosts Upcoming Webinar to Help Health Professionals Distinguish Lyme Disease, Flu and COVID-19 During Frightening Respiratory Season

  11/19/2020

  With the common symptoms of flu, COVID-19 and Lyme disease all converging to form a frightening respiratory season, health care professionals nationwide will converge themselves to join an important webinar on Dec. 3 focused on how to correctly diagnose and treat these look-alike conditions. The webinar is being sponsored by Quidel, the California-based diagnostic health care manufacturer known for successfully developing ra

• Quidel to Present at Upcoming Conferences - Nov 10, 2020

  11/10/2020

  Quidel Corporation, a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that it will present at the following upcoming conferences

• Quidel Corporation Triple Winner in International MarCom Awards Competition

  11/10/2020

  Quidel Corporation has been honored with three awards for creative excellence from the international MarCom Awards competition, just announced. Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, the Sofia® 2 Lyme FIA test. The MarCom Awards is an international creative competition that recognizes outstanding achievement by marketing and commun

• Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29th, 2020

  10/19/2020

  Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29 th , 2020

• Quidel Receives Emergency Authorization for First Rapid Antigen “ABC Test”: A Combination Diagnostic Assay for Influenza A+B and COVID-19

  10/2/2020

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to market its Sofia® 2 Flu + SARS Antigen FIA,

• Quidel Announces Preliminary Revenue for Third Quarter 2020

  10/1/2020

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it expects revenues in the third fiscal quarter of 2020 to be in the range of $475 million to $477 million.

• Quidel Corporation Statement on President Trump’s Announcement of Coronavirus Testing Strategy

  9/28/2020

  Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, issued the following statement supporting the Administration’s plans to provide COVID-19 rapid tests to school children. “Quidel Corporation welcomes President Trump’s announcement that the Administration will direct millions of Abbott’s visually read antigen t